5% Off
Doripen500 mg/via
Eskayef Bangladesh Ltd.
৳1900.00
Add to cart
Dorinem500 mg/vial
IV Infusion
By
Best PriceTk /
1
Medicine overview
Indications of Dorinem 500 mg/vial
they should be considered in selecting and modifying antibacterial therapy. In the absence of such dataKlebsiella pneumoniaePseudomonas aeruginosaBacteroides caccaeBacteroides fragilisBacteroides thetaiotaomicronBacteroides uniformisBacteroides vulgatusStreptococcus intermediusStreptococcus constellatus and Peptostreptococcus micros.Complicated Urinary Tract Infectionsincluding pyelonephritis caused by Escherichia coli including cases with concurrent bacteremiaKlebsiella pneumoniaeProteus mirabilisPseudomonas aeruginosa and Acinetobacter baumannii.
Theropeutic Class
Other beta-lactam Antibiotics
Pharmacology
Dorinem 500 mg/vial is a synthetic broad-spectrum carbapenem β-lactam antibiotic with potent in vitro antibacterial activity against aerobic and anaerobic gm+ve and gm-ve bacteria including Pseudomonas aeruginosa.
Absorption
It inhibits bacterial cell wall synthesis by binding to several penicillin-binding proteins, which in turn inhibits the final transpeptidase step of peptidoglycan synthesis in bacterial cell walls.
Dosage & Administration of Dorinem 500 mg/vial
Intravenous- Complicated intra-abdominal infections
Dosage:500 mg 8 hrly infused over 1 hr for 5-14 days
Notes:May switch to an appropriate oral therapy, after at least 3 days of parenteral therapy
Complicated UTI, Pyelonephritis
Dosage:500 mg 8 hrly infused over 1 hr for 10 days
Notes:May switch to an appropriate oral therapy, after at least 3 days of parenteral therapy
Patient with concurrent bacteraemia
Dosage:Duration can be extended up to 14 days
Renal impairment- CrCI (30-50 ml/min)
Dosage:250 mg every 8 hr by IV infusion over 1 hr CrCI (11 -29 ml/min): 250 mg every 12 hr by IV infusion over 1 hr
| Condition | Dosage | Notes |
|---|---|---|
| Intravenous- Complicated intra-abdominal infections | 500 mg 8 hrly infused over 1 hr for 5-14 days | May switch to an appropriate oral therapy, after at least 3 days of parenteral therapy |
| Complicated UTI, Pyelonephritis | 500 mg 8 hrly infused over 1 hr for 10 days | May switch to an appropriate oral therapy, after at least 3 days of parenteral therapy |
| Patient with concurrent bacteraemia | Duration can be extended up to 14 days | |
| Renal impairment- CrCI (30-50 ml/min) | 250 mg every 8 hr by IV infusion over 1 hr CrCI (11 -29 ml/min): 250 mg every 12 hr by IV infusion over 1 hr |
Dosage of Dorinem 500 mg/vial
Intravenous- Complicated intra-abdominal infections
Dosage:500 mg 8 hrly infused over 1 hr for 5-14 days
Notes:May switch to an appropriate oral therapy, after at least 3 days of parenteral therapy
Complicated UTI, Pyelonephritis
Dosage:500 mg 8 hrly infused over 1 hr for 10 days
Notes:May switch to an appropriate oral therapy, after at least 3 days of parenteral therapy
Patient with concurrent bacteraemia
Dosage:Duration can be extended up to 14 days
Renal impairment- CrCI (30-50 ml/min)
Dosage:250 mg every 8 hr by IV infusion over 1 hr CrCI (11 -29 ml/min): 250 mg every 12 hr by IV infusion over 1 hr
| Condition | Dosage | Notes |
|---|---|---|
| Intravenous- Complicated intra-abdominal infections | 500 mg 8 hrly infused over 1 hr for 5-14 days | May switch to an appropriate oral therapy, after at least 3 days of parenteral therapy |
| Complicated UTI, Pyelonephritis | 500 mg 8 hrly infused over 1 hr for 10 days | May switch to an appropriate oral therapy, after at least 3 days of parenteral therapy |
| Patient with concurrent bacteraemia | Duration can be extended up to 14 days | |
| Renal impairment- CrCI (30-50 ml/min) | 250 mg every 8 hr by IV infusion over 1 hr CrCI (11 -29 ml/min): 250 mg every 12 hr by IV infusion over 1 hr |
Interaction of Dorinem 500 mg/vial
Increased plasma concentration with probenecid. May decrease plasma levels of valproic acid thus, increasing the risk of seizures.
Contraindications
Hypersensitivity to Dorinem 500 mg/vial, other carbapenem antibacterial agents; history of anaphylactic reaction to β-lactams (e.g. penicillins, cephalosporins).
Side Effects of Dorinem 500 mg/vial
Headache, nausea, diarrhoea, rash, pruritus, phlebitis, elevated hepatic enzymes, oral candidiasis, anaemia, vulvomycotic infection, thrombocytopenia, neutropenia.
Pregnancy & Lactation
Pregnancy Category B. Either animal-reproduction studies have not demonstrated a fetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters).
Precautions & Warnings
Patient with known or suspected CNS disorders (e.g. brain lesions, history of seizures). Not intended for treatment of any type of pneumonia. Renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor renal function and for signs of anaphylaxis during 1st dose. Consider haematologic assessment during prolonged therapy.
Storage Conditions
Reconstituted suspension may be held for 1 hr prior to dilution in infusion bag. Following dilution of the suspension with NaCl 0.9%, stability is 8 hr at room temperature or 24 hr between 2-8°C. Stability of solution when diluted with dextrose 5% injection is 4 hr at room temperature or 24 hr between 2-8°C.
Drug Classes
Other beta-lactam Antibiotics
Mode Of Action
Dorinem 500 mg/vial is a synthetic broad-spectrum carbapenem β-lactam antibiotic with potent in vitro antibacterial activity against aerobic and anaerobic gm+ve and gm-ve bacteria including Pseudomonas aeruginosa. It inhibits bacterial cell wall synthesis by binding to several penicillin-binding proteins, which in turn inhibits the final transpeptidase step of peptidoglycan synthesis in bacterial cell walls.
Pregnancy
Pregnancy Category B. Either animal-reproduction studies have not demonstrated a fetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters).
Frequently Asked Questions
What is Dorinem 500 mg/vial used for?
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doripenem and other antibacterial drugs, Doripenem should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are ... Read moreTo reduce the development of drug-resistant bacteria and maintain the effectiveness o…
What is the dosage of Dorinem 500 mg/vial?
Intravenous- Complicated intra-abdominal infections: 500 mg 8 hrly infused over 1 hr for 5-14 days. May switch to an appropriate oral therapy, after at least 3 days of parenteral therapy. Complicated UTI, Pyelonephritis: 500 mg 8 hrly infused over 1 hr for 10 days. May switch to an appropriate oral therapy, after at least 3 days of parenteral therapy. Patient with concurrent bacteraemia: Duration …
What are the side effects of Dorinem 500 mg/vial?
Headache, nausea, diarrhoea, rash, pruritus, phlebitis, elevated hepatic enzymes, oral candidiasis, anaemia, vulvomycotic infection, thrombocytopenia, neutropenia.
Who should not take Dorinem 500 mg/vial?
Hypersensitivity to doripenem, other carbapenem antibacterial agents; history of anaphylactic reaction to β-lactams (e.g. penicillins, cephalosporins).
What precautions should be taken with Dorinem 500 mg/vial?
Patient with known or suspected CNS disorders (e.g. brain lesions, history of seizures). Not intended for treatment of any type of pneumonia. Renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor renal function and for signs of anaphylaxis during 1st dose. Consider haematologic assessment during prolonged therapy.
Is Dorinem 500 mg/vial safe during pregnancy and breastfeeding?
Pregnancy Category B. Either animal-reproduction studies have not demonstrated a fetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters).
Disclaimer
The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.